ArticleCurrent health sciences journal
Immunoexpression of Claudin-4 In Non-Small Cell Lung Carcinomas.
Article in Current health sciences journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Claudin proteins as emerging therapeutic targets for solid tumours.Nature reviews. Cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung carcinomas (NSCLC) are the most common histological forms of lung cancer, lesions that by their incidence and associated mortality constitute a health problem worldwide. Alteration of the expression of claudins with a role in the stability of cell adhesion constitutes one of the complex biomolecular mechanisms involved in tumor initiation and progression. In this study, Claudin-4 immunoexpression was investigated in 52 cases of NSCLC in relation to epidemiological and histopathological prognostic parameters of the lesions. Although the staining scores were higher in patients in younger age groups, in women, in smokers and in squamous cell carcinomas (SCC) and large cell carcinoma (LLC) compared to adenocarcinomas (ADK), the aspects were not statistically significant. We found significantly higher differences in micropapillary, cribriform and solid ADK compared to other histological subtypes, in well and poorly differentiated lesions (G1/G3), with vascular invasion and in advanced tumor stages. Reaction analysis indicated translocation of Claudin-4 signals from the membrane level to the cytoplasm and nucleus in aggressive histological subtypes. The study indicated differences in Claudin-4 expression, which can be used to identify aggressive NSCLC and to stratify patients for specific therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.